In an in vivo model of glioblastoma multiforme, human CMV/HSV-1 oncolytic virotherapy elicited an immune response characterized by the significant induction of CD8+ T cells, but not CD4+ T cells [94]. The gene discussed is CD8A; the disease is glioblastoma.